- Home
- SILC vs MCRB Comparison
SILC vs MCRB Comparison
Compare SILC & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- MCRB
- Stock Information
- Founded
- SILC 1987
- MCRB 2010
- Country
- SILC Israel
- MCRB United States
- Employees
- SILC N/A
- MCRB N/A
- Industry
- SILC Computer Manufacturing
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- MCRB Health Care
- Exchange
- SILC Nasdaq
- MCRB Nasdaq
- Market Cap
- SILC 84.7M
- MCRB 72.0M
- IPO Year
- SILC 1994
- MCRB 2015
- Fundamental
- Price
- SILC $15.40
- MCRB $8.03
- Analyst Decision
- SILC Hold
- MCRB Hold
- Analyst Count
- SILC 2
- MCRB 5
- Target Price
- SILC N/A
- MCRB $73.67
- AVG Volume (30 Days)
- SILC 10.0K
- MCRB 87.0K
- Earning Date
- SILC 07-28-2025
- MCRB 05-07-2025
- Dividend Yield
- SILC N/A
- MCRB N/A
- EPS Growth
- SILC N/A
- MCRB N/A
- EPS
- SILC N/A
- MCRB 8.98
- Revenue
- SILC $58,134,000.00
- MCRB N/A
- Revenue This Year
- SILC $6.26
- MCRB N/A
- Revenue Next Year
- SILC $19.14
- MCRB N/A
- P/E Ratio
- SILC N/A
- MCRB $0.92
- Revenue Growth
- SILC N/A
- MCRB N/A
- 52 Week Low
- SILC $11.35
- MCRB $6.53
- 52 Week High
- SILC $18.24
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- SILC 56.33
- MCRB 49.99
- Support Level
- SILC $14.20
- MCRB $6.96
- Resistance Level
- SILC $15.48
- MCRB $8.47
- Average True Range (ATR)
- SILC 0.72
- MCRB 0.47
- MACD
- SILC -0.03
- MCRB 0.25
- Stochastic Oscillator
- SILC 93.79
- MCRB 73.86
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.